Epkinly (pTAP negotiation) (epcoritamab)

Numéro de dossier de l’AMC: 22708
État des négociations:
En négociation
Indication(s):
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b) after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
Promoteur/fabricant:
AbbVie Corporation
Numéro de projet de l’AMC:
PC0334-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Sans objet